Guardant Health Investor Presentation

LUNAR- 1: Selecting patients with residual disease for adjuvant therapy may improve outcomes in multiple cancers Breast e.g., Herceptin Nearly 50% reduction in risk of recurrence(1) (1) N Engl J Med 2005;353:1659-72. Lung CRC Ovarian No well-defined standard for accurately selecting patients for adjuvant therapy 23 GUARDANT

View entire presentation